Abstract
A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have